JPWO2022015922A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022015922A5 JPWO2022015922A5 JP2023503124A JP2023503124A JPWO2022015922A5 JP WO2022015922 A5 JPWO2022015922 A5 JP WO2022015922A5 JP 2023503124 A JP2023503124 A JP 2023503124A JP 2023503124 A JP2023503124 A JP 2023503124A JP WO2022015922 A5 JPWO2022015922 A5 JP WO2022015922A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- trp
- phe
- Prior art date
Links
- 150000001413 amino acids Chemical group 0.000 claims 51
- 108090000765 processed proteins & peptides Proteins 0.000 claims 32
- 229920001184 polypeptide Polymers 0.000 claims 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims 29
- 108091008874 T cell receptors Proteins 0.000 claims 23
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 22
- 210000004027 cell Anatomy 0.000 claims 22
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 20
- 150000007523 nucleic acids Chemical class 0.000 claims 13
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 102000004169 proteins and genes Human genes 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 102000016914 ras Proteins Human genes 0.000 claims 10
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 claims 8
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 239000013604 expression vector Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 238000003259 recombinant expression Methods 0.000 claims 7
- 102100029974 GTPase HRas Human genes 0.000 claims 6
- 102100030708 GTPase KRas Human genes 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 239000013598 vector Substances 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 206010029260 Neuroblastoma Diseases 0.000 claims 3
- 108700020796 Oncogene Proteins 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 claims 2
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 2
- 239000000833 heterodimer Substances 0.000 claims 2
- 102000043600 human HRAS Human genes 0.000 claims 2
- 102000049555 human KRAS Human genes 0.000 claims 2
- 102000047526 human NRAS Human genes 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 102100040505 HLA class II histocompatibility antigen, DR alpha chain Human genes 0.000 claims 1
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 claims 1
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 1
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 1
- 108010053491 HLA-DR beta-Chains Proteins 0.000 claims 1
- 108010039343 HLA-DRB1 Chains Proteins 0.000 claims 1
- 101150018610 HLA-DRB1 gene Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000581 natural killer T-cell Anatomy 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000009258 tissue cross reactivity Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063052502P | 2020-07-16 | 2020-07-16 | |
| US63/052,502 | 2020-07-16 | ||
| PCT/US2021/041737 WO2022015922A1 (en) | 2020-07-16 | 2021-07-15 | Hla class ii-restricted drb t cell receptors against ras with g12v mutation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023535366A JP2023535366A (ja) | 2023-08-17 |
| JPWO2022015922A5 true JPWO2022015922A5 (pt) | 2024-07-18 |
Family
ID=77265247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023503124A Pending JP2023535366A (ja) | 2020-07-16 | 2021-07-15 | Ｇ１２ｖ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｄｒｂ ｔ細胞受容体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230257440A1 (pt) |
| EP (1) | EP4182029A1 (pt) |
| JP (1) | JP2023535366A (pt) |
| KR (1) | KR20230046294A (pt) |
| CN (1) | CN116348484A (pt) |
| AU (1) | AU2021309958A1 (pt) |
| CA (1) | CA3185483A1 (pt) |
| WO (1) | WO2022015922A1 (pt) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2497552C (en) | 2002-09-06 | 2014-05-27 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| SG11202002425PA (en) * | 2017-09-20 | 2020-04-29 | The United States Of America As Represented By The Secretary | Hla class ii-restricted t cell receptors against mutated ras |
-
2021
- 2021-07-15 EP EP21752355.4A patent/EP4182029A1/en active Pending
- 2021-07-15 WO PCT/US2021/041737 patent/WO2022015922A1/en unknown
- 2021-07-15 CN CN202180050745.7A patent/CN116348484A/zh active Pending
- 2021-07-15 JP JP2023503124A patent/JP2023535366A/ja active Pending
- 2021-07-15 KR KR1020237005176A patent/KR20230046294A/ko unknown
- 2021-07-15 CA CA3185483A patent/CA3185483A1/en active Pending
- 2021-07-15 US US18/015,781 patent/US20230257440A1/en active Pending
- 2021-07-15 AU AU2021309958A patent/AU2021309958A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7256794B2 (ja) | 変異型ｒａｓに対するｈｌａクラスｉｉ拘束性ｔ細胞受容体 | |
| Boyson et al. | Identification of a novel MHC class I gene, Mamu-AG, expressed in the placenta of a primate with an inactivated G locus. | |
| AU2018259029B2 (en) | TCR and peptides | |
| Fujii et al. | A soluble form of the HLA-G antigen is encoded by a messenger ribonucleic acid containing intron 4. | |
| JP2021505136A5 (pt) | ||
| RU2752528C2 (ru) | Композиции и библиотеки, содержащие рекомбинантные полинуклеотиды, кодирующие Т-клеточные рецепторы, и способы применения рекомбинантных Т-клеточных рецепторов | |
| KR20230079259A (ko) | Kras 돌연변이 특이적 t세포 수용체의 스크리닝 및 항종양 용도 | |
| JP2020534828A5 (pt) | ||
| Elliott | Transporter associated with antigen processing | |
| JPH1057075A (ja) | Ｔ細胞抗原受容体β鎖ポリペプチド断片 | |
| GB2609760A (en) | HLA Class I-restricted T cell receptors against RAS with G12D mutation | |
| CN111032686B (zh) | 血液恶性肿瘤的治疗 | |
| Takamiya et al. | HLA-B* 3501–peptide interactions: role of anchor residues of peptides in their binding to HLA-B* 3501 molecules | |
| Fellah et al. | Conserved structure of amphibian T-cell antigen receptor beta chain. | |
| JP2023527613A (ja) | Ｇ１２ｖ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｔ細胞受容体 | |
| JP2023526149A (ja) | Ｇ１２ｖ突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体 | |
| Sievers et al. | Glycoprotein B from strain 17 of herpes simplex virus type I contains an invariant chain homologous sequence that binds to MHC class II molecules | |
| JP3067777B2 (ja) | アルファー遺伝子座中に位置するｔ細胞レセプター遺伝子およびｄｎａ構成物 | |
| JPWO2022015922A5 (pt) | ||
| US8658177B2 (en) | Promiscuous HER-2/Neu CD4 T cell epitopes | |
| JPWO2020154275A5 (pt) | ||
| JPWO2022015694A5 (pt) | ||
| Hayball et al. | The immune function of MHC class II molecules mutated in the putative superdimer interface | |
| JP2023535366A (ja) | Ｇ１２ｖ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｄｒｂ ｔ細胞受容体 | |
| NZ805541A (en) | Hla class i-restricted t cell receptors against mutated ras |